Detalhe da pesquisa
1.
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma.
Blood
; 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38728378
2.
Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.
Blood
; 141(19): 2359-2371, 2023 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36626250
3.
The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantation.
Br J Haematol
; 203(5): 840-851, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37614192
4.
Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study.
Blood
; 137(11): 1527-1537, 2021 03 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33512409
5.
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach.
Am J Hematol
; 98(3): 421-431, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36588413
6.
A prospective study of dysgeusia and related symptoms in patients with multiple myeloma after autologous hematopoietic cell transplantation.
Cancer
; 128(21): 3850-3859, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36041227
7.
Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis.
Biol Blood Marrow Transplant
; 26(1): 204-208, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31446197
8.
Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma.
Biol Blood Marrow Transplant
; 26(1): 58-65, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31493537
9.
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.
Biol Blood Marrow Transplant
; 26(8): 1394-1401, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32442725
10.
Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma.
Biol Blood Marrow Transplant
; 26(11): 2040-2046, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32712326
11.
Reduction of Opioid Use by Acupuncture in Patients Undergoing Hematopoietic Stem Cell Transplantation: Secondary Analysis of a Randomized, Sham-Controlled Trial.
Pain Med
; 21(3): 636-642, 2020 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31498394
12.
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.
Biol Blood Marrow Transplant
; 24(4): 871-876, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29288818
13.
Acupuncture for reduction of symptom burden in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a randomized sham-controlled trial.
Support Care Cancer
; 26(2): 657-665, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28920142
14.
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.
Biol Blood Marrow Transplant
; 22(2): 258-267, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26325439
15.
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.
Blood
; 124(6): 899-906, 2014 Aug 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-24963043
16.
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2 ) in combination with lenalidomide and dexamethasone.
Am J Hematol
; 96(6): E193-E196, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33661527
17.
Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1.
Blood
; 119(22): 5182-90, 2012 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-22510877
18.
Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy.
Transplant Cell Ther
; 30(1): 116.e1-116.e12, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37806446
19.
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.
Blood Adv
; 8(7): 1600-1611, 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37878808
20.
Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy.
Blood Adv
; 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38598713